Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -37.08% is 95% above its 2-year average of -762.26%, near the high end of its 2-year range (-3106.20%–54.26%).
94.96% above its 12-month average of -735.82%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -526.49%.
EBITDA MARGIN
-37.08%
EBITDA MARGIN AVG TTM
-735.82%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+94.96%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Monte Rosa Therapeutics, Inc.
Market Cap
$854.51M
EBITDA Margin
-37.08%
TTM Avg
-735.82%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$852.44M
EBITDA Margin
-68.63%
TTM Avg
-68.17%
3Y Avg
-9114.49%
5Y Avg
-9114.49%
Market Cap
$875.38M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$828.85M
EBITDA Margin
-1761.78%
TTM Avg
-1761.78%
3Y Avg
-1761.78%
5Y Avg
-1761.78%
Market Cap
$888.92M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$818.90M
EBITDA Margin
-9.31%
TTM Avg
-8.54%
3Y Avg
-46.73%
5Y Avg
-472.39%
Market Cap
$817.21M
EBITDA Margin
12.02%
TTM Avg
14.44%
3Y Avg
-4.83%
5Y Avg
-238.26%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $854.51M | -37.08% | -735.82% | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.44M | -68.63% | -68.17% | -9114.49% | -9114.49% |
| Apnimed, Inc. (APMD)vs › | $839.87M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.38M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $833.10M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $828.85M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
| Arbutus Biopharma Corp (ABUS)vs › | $888.92M | -189.51% | -701.94% | -497.69% | -575.23% |
| Ardelyx, Inc. (ARDX)vs › | $818.90M | -9.31% | -8.54% | -46.73% | -472.39% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $817.21M | 12.02% | 14.44% | -4.83% | -238.26% |
| InMode Ltd. (INMD)vs › | $809.62M | 23.23% | 25.96% | 33.88% | 36.34% |
Gross Margin
92.9%
EBITDA Margin
-37.1%
Operating Margin
-43.8%
Net Margin
-560.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -526.49% |
| 2026-03-31 | -1140.26% |
| 2025-12-31 | -1712.59% |
| 2025-09-30 | -241.85% |
| 2025-06-30 | -57.90% |
| 2025-03-31 | 54.26% |
| 2024-12-31 | 24.84% |
| 2024-09-30 | -265.02% |
| 2024-06-30 | -651.37% |
| 2024-03-31 | -3106.20% |
